Wedbush reiterated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a report issued on ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other ...

Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Scholar Rock (NASDAQ:SRRK – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA.